Combination Radiotherapy with Brachytherapy, Associated with excellent 3- and 5- year Disease-Free survival rates in Patients with clinically localized prostate cancer and high PSA levels.

At the 2005 Multidsplinary Wordl Prostate Cancer Symposium, held at Orlando (USA), Doctors Raboy & Albert, from Staten Island University Hospital (NY) presented intermediate and long-term results (3 and 5 year) in 1090 patients with localized prostate cancer with high PSA levels (>=20 ng/ml).

Treatment consisted in Conforma 3D external beam radiotherapy followed by an intersticial implant to the prostate either with iodine-125 or HDR brachytherapy. PSA values were determined at 6 and 12 months after treatment and since then in a yearly basis. Mean age was 68,7 years, mean initial PSA 36,5 ng/ml and mean Gleason score 6,4.

With an average follow-up of 6.52 years (range 3-12), the cumulative probability of patients remaining biochemically free of prostate disease at 3 and 5 years was 95 and 89 respectively. Disease-free survival was not statiscally significant when patients were stratified by Gleason score. In conclusion, authors demonstrated tha combination treatment with 3D-conformal Radiotherapy + Brachytherapy is the best treatment option existing today for localized prostate cancer with high PSA values.

At IMOR Foundation, combined treatment with 3D-conformal radiotherapy + Brachytherapy were initiated more tha 5 years ago. Since then, more than 350 patients have been included in the protocol. Results obtained are excellent, with a 3- and 5- year survival rates unknown up-to nowadays for this tumors and with a very low long-term side-effects rate.

Volver a la pagina principal: ../index.htm